IP Library Granted Patent US 9,603,931
Granted Patent B2
US 9,603,931 · App. 13/519,729 · Granted Mar 28, 2017

Macromolecule for delivering protein, polypeptide or peptide drugs and a production method for the same, and a slow release composition for protein, polypeptide or peptide drugs and a production method for the same

Inventors: Yil Woong Yi (Daejeon, KR); Min Hyo Seo (Daejeon, KR); Bong Oh Kim (Daejeon, KR); In Ja Choi (Daejeon, KR); Hye Jeong Yoon (Daejeon, KR); Se Yoon Kim (Seoul, KR); Sang Jun Lee (Daejeon, KR); Joong Woong Cho (Daejeon, KR)
Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATION
A61K47/34C07C67/465C07C69/68C08G63/06C08G63/912C08J3/215C08J2367/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,603,931
App. No.
13/519,729
Granted
Mar 28, 2017
Kind
B2
Abstract

The present invention relates to a macromolecule for delivering protein, polypeptide or peptide drugs and to a production method for the same, as well as to a slow release composition for protein, polypeptide or peptide drugs comprising the same, and more specifically relates to a polylactic acid derivative compound of Chemical formula 1 of which the numerical average molecular weight is no more than 7000 daltons and to a production method for the same, as well as to a slow release composition for protein, polypeptide or peptide drugs using the same and to a production method for the same.

Claims (22)

1. A sustained release microparticle composition of protein, polypeptide or peptide drug, consisting of:

i) a protein, polypeptide or peptide as an active ingredient, and

ii) a complex of a water-soluble ionic polymer of the following chemical formula 6 having a number average molecular weight of 1,000 to 4,000 daltons with a multivalent metal ion, as a drug delivery carrier;

wherein

X and X′ are independently hydrogen, alkyl or aryl,

m and n are independently an integer of 0 to 95, provided that 5<m+n<100,

a and b are independently an integer of 1 to 6,

R is unsubstituted or substituted —(CH 2 ) k — where k is an integer of 0 to 10, a divalent alkenyl having 2 to 10 carbon atoms, a divalent aryl having 6 to 20 carbon atoms, or a combination thereof;

wherein said active ingredient is entrapped within the complex.

2. The sustained release microparticle composition according to claim 1 , which contains said active ingredient in an amount of 0.01 to 60 wt %, based on the dry weight of the composition.

3. The sustained release microparticle composition according to claim 1 , which contains said drug delivery carrier in an amount of 39.9 to 99.9 wt %, based on the dry weight of the composition.

4. The sustained release microparticle composition according to claim 1 , wherein said active ingredient is growth hormone, erythropoietin, monoclonal antibody, granulocyte colony stimulating factor, macrophage colony stimulating factor, granulocyte-macrophage colony stimulating factor, thrombopoietin, insulin-like growth factor, epithelial growth factor, platelet-derived growth factor, fibroblast growth factor, transforming growth factor, interferon, interleukin, tumor necrosis factor, streptokinase, urokinase, staphylokinase, DNAse, glucocerebrosidase, alpha galactosidase, exenatide, octreotide, insulin, glucagon, luteinizing hormone releasing hormone, goserelin, leuprorelin, follicle stimulating factor, thyroid stimulating hormone, fertirelin, calcitonin, corticotropin releasing factor, brain natriuretic peptide, thymopentin, corticotropin, elcatonin, beta amyloid, triptorelin, buserelin, thymosin, somatostatin, alarelin, angiotensin, argipressin, atosiban, bivalirudin, cetrorelix, deslorelin, desmopressin, elcatonin, enfuvirtide, eptifibatide, GLP-1, gonandorelin, lyspressin, nafarelin, nesiritide, oxytocin, pramlintide, secretin, teriparatide, terlipressin, tetracosactide, vapreotide, or a mixture thereof.

5. A sustained release microparticle composition of protein, polypeptide or peptide drug, consisting of:

i) a protein, polypeptide or peptide as an active ingredient;

ii) a complex of a water-soluble ionic polymer of the following chemical formula 6 having a number average molecular weight of 1,000 to 4,000 daltons with a multivalent metal ion, as a drug delivery carrier:

wherein

X and X′ are independently hydrogen, alkyl or aryl,

m and n are independently an integer of 0 to 95, provided that 5<m+n<100,

a and b are independently an integer of 1 to 6,

R is unsubstituted or substituted —(CH 2 ) k — where k is an integer of 0 to 10, a divalent alkenyl having 2 to 10 carbon atoms, a divalent aryl having 6 to 20 carbon atoms, or a combination thereof; and

iii) a lyophilizing adjuvant,

wherein said active ingredient is entrapped within the complex.

Assignments (3)
CHANGE OF ADDRESS Recorded Nov 3, 2021
From: SAMYANG BIOPHARMACEUTICALS CORPORATION
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 058013/0696 →
MERGER Recorded Nov 3, 2021
From: SAMYANG BIOPHARMACEUTICALS CORPORATION
To: SAMYANG HOLDINGS CORPORATION
Reel/Frame 058013/0766 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2012
From: YI, YIL WOONG; SEO, MIN HYO; KIM, BONG OH; CHOI, IN JA; YOON, HYE JEONG; KIM, SE YOON; LEE, SANG JUN; CHO, JOONG WOONG
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 028471/0747 →
Priority Claims (1)
KR 10-2009-0132861 · Dec 29, 2009 · national
Continuity (1)
Related Publication 20130274188A1 · Oct 17, 2013